A randomised clinical study of alfacalcidol and paricalcitol: Two vitamin D analogs for treatment of secondary hyperparathyroidism in chronic hemodialysis patients

Danish Medical Journal

Volumn 59, Issue 2, 2012, Pages

  Hansen, Ditte ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE;

ARTICLE; DENMARK; DISEASE ASSOCIATION; DISEASE SEVERITY; HEMODIALYSIS; HUMAN; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PULSE WAVE; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY HYPERPARATHYROIDISM;

EID: 84873174300     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (275)

1. The Danish Society of Nephrology. Danish Nephrology Registry Annual Report 2009. 2010.
2. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; S1-130
3. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38
4. Nykjaer A, Dragun D, Walther D et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96: 507-515
5. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; doi:10.1038/ki.2011.47
6. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
7. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-28
8. Usatii M, Rousseau L, Demers C et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1, 25 (OH) 2D synthesis. Kidney Int 2007; 72: 1330-1335
9. Kumar R, Thompson JR. The Regulation of Parathyroid Hormone Secretion and Synthesis. J Am Soc Nephrol 2010; 2: 216-224
10. Brown AJ, Dusso A, Lopez-Hilker S, Lewis-Finch J, Grooms P, Slatopolsky E. 1, 25-(OH) 2D receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int 1989; 35: 19-23
11. Lewin E, Rodriguez M. Abnormal parathyroid gland function in CKD. In: Olgaard K, Salusky IB, Silver J, eds. The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Oxford University Press, 2010; 77-107
12. Martin KJ, Olgaard K, Coburn JW et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43: 558-565
13. Slatopolsky E, Gonzalez E, Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003; 21: 318-326
14. Coen G, Ballanti P, Bonucci E et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002; 91: 103-111
15. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26: 836-844
16. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156
17. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366
18. Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18: 2401-2407
19. Mitterbauer C, Kramar R, Oberbauer R. Age and sex are sufficient for predicting fractures occurring within 1 year of hemodialysis treatment. Bone 2007; 40: 516-521
20. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
21. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
22. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97
23. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
24. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
25. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO (4), Ca x PO (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
26. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
27. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528
28. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K. Outcomes associated with serum calcium level in men with nondialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 468-476
29. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357
30. Naves-Diaz M, Passlick-Deetjen J, Guinsburg A et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2010; 10.1093/ndt/gfq304 [doi]
31. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005; 46: 68-77
32. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793
33. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
34. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964
35. Goodman WG, London G, Amann K et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43: 572-579
36. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867
37. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
38. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701
39. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
40. Miller JE, Kovesdy CP, Norris KC et al. Association of cumulatively low or high serum calcium levels with mortality in longterm hemodialysis patients. Am J Nephrol 2010; 32: 403-413
41. Carafoli E, Penniston JT. The calcium signal. Sci Am 1985; 253: 70-78
42. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003; 24: 2054-2060
43. Schluter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998; 37: 34-41
44. Jean G, Lataillade D, Genet L et al. Association between Very Low PTH Levels and Poor Survival Rates in Haemodialysis Patients: Results from the French ARNOS Cohort. Nephron Clin Pract 2010; 118: c211-c216
45. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835
46. Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38: 1351-1357
47. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201
48. Daugaard H, Heaf J, Joffe P et al. Forstyrrelser i knogle-og mineralomsatningen ved kronisk nyresygdom. Guidelines for diagnostik og behandling. 2005;
49. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-1127
50. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013
51. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2008; 75: 88-95
52. Mehrotra R, Kermah DA, Salusky IB et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009; 76: 977-983
53. Kilkkinen A, Knekt P, Aro A et al. Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol 2009; 170: 1032-1039
54. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637
55. Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511
56. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456
57. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184
58. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125
59. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865
60. Lee GH, Benner D, Regidor DL, Kalantar-Zadeh K. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 2007; 17: 38-44
61. Naves-Diaz M, varez-Hernandez D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078
62. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403
63. Shoben AB, Rudser KD, de B, I, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619
64. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-72
65. Shinaberger CS, Kopple JD, Kovesdy CP et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1769-1776
66. St Peter WL, Li S, Liu J, Gilbertson DT, Arneson TJ, Collins AJ. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis. Pharmacotherapy 2009; 29: 154-164
67. Sugiura S, Inaguma D, Kitagawa A et al. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol 2010; 14: 43-50
68. Jean G, Lataillade D, Genet L et al. Impact of Hypovitaminosis D and Alfacalcidol Therapy on Survival of Hemodialysis Patients: Results from the French ARNOS Study. Nephron Clin Pract 2010; 118: c204-c210
69. Jean G, Lataillade D, Genet L et al. Impact of Hypovitaminosis D and Alfacalcidol Therapy on Survival of Hemodialysis Patients: Results from the French ARNOS Study. Nephron Clin Pract 2010; 118: c204-c210
70. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2009; CD005633
71. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; CD008175
72. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730-1737
73. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152: 315-323
74. Kuroo M. Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab 2008; 19: 239-245
75. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008
76. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 2004; 29: 91-99
77. Saito H, Kusano K, Kinosaki M et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate cotransport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278: 2206-2211
78. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alphahydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293: F1577-F1583
79. Yoshida T, Fujimori T, Nabeshima Y. Mediation of unusually high concentrations of 1, 25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology 2002; 143: 683-689
80. Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alphahydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125-131
81. Canalejo R, Canalejo A, Martinez-Moreno JM et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010; 21: 1125-1135
82. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218
83. Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77: 232-238
84. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279
85. Imanishi Y, Inaba M, Nakatsuka K et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65: 1943-1946
86. Barthel TK, Mathern DR, Whitfield GK et al. 1, 25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 2007; 103: 381-388
87. Ito M, Sakai Y, Furumoto M et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 2005; 288: E1101-E1109
88. Kolek OI, Hines ER, Jones MD et al. 1alpha, 25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005; 289: G1036-G1042
89. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-2549
90. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE. Genetic dissection of phosphate-and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 2005; 36: 971-977
91. Wesseling-Perry K, Wolf M. FGF23 in renal failure. In: Olgaard K, Salusky IB, Silver J, eds. The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Oxford University Press, 2010; 405-415
92. Kawata T, Imanishi Y, Kobayashi K et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18: 2683-2688
93. Lopez I, Rodriguez-Ortiz ME, Almaden Y et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 2011; 10.1038/ki.2011.107
94. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095
95. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095
96. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
97. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796
98. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
99. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552
100. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25: 3983-3989
101. Saarem K, Pedersen JI. 25-Hydroxylation of 1 alphahydroxyvitamin D-3 in rat and human liver. Biochim Biophys Acta 1985; 840: 117-126
102. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277: F157-F175
103. Dusso AS, Finch J, Brown A et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991; 72: 157-164
104. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81: 353-373
105. Somjen D, Weisman Y, Kohen F et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111: 1666-1671
106. Brandi L. 1alpha (OH) D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Dan Med Bull 2008; 55: 186-210
107. Hansen D, Brandi L, Rasmussen K. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol. BMC Nephrol 2009; 10: 28
108. Holick MF, Semmler EJ, Schnoes HK, DeLuca HF. 1-Hydroxy derivative of vitamin D 3: a highly potent analog of 1, 25-dihydroxyvitamin D 3. Science 1973; 180: 190-191
109. Holick MF, Semmler EJ, Schnoes HK, DeLuca HF. 1-Hydroxy derivative of vitamin D 3: a highly potent analog of 1, 25-dihydroxyvitamin D 3. Science 1973; 180: 190-191
110. Chalmers TM, Hunter JO, Davie MW, Szaz KF, Pelc B, Kodicek E. 1-Alpha-hydroxycholecalciferol as a substitute for the kidney hormone 1, 25-dihydroxycholecalciferol in chronic renal failure. Lancet 1973; 2: 696-699
111. Madsen S. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3. Acta Med Scand Suppl 1980; 638:3-120.: 3-120
112. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990; 86: 1313-1319
113. Russell J, Lettieri D, Sherwood LM. Suppression by 1, 25 (OH) 2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986; 119: 2864-2866
114. Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrology (Carlton) 2011; 16: 277-284
115. Shigematsu T, Kawaguchi Y, Unemura S et al. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1, 25-dihydroxycholecalciferol. Intern Med 1993; 32: 695-701
116. Brandi L, Daugaard H, Tvedegaard E et al. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 1992; 12: 311-318
117. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 2004; 19: 870-876
118. Tougaard L, Sorensen E, Brochner-Mortensen J, Christensen MS, Rodbro P, Sorensen AW. Controlled trial of 1aphahydroxycholecalciferol in chronic renal failure. Lancet 1976; 1: 1044-1047
119. Brandi L, Egfjord M, Olgaard K. Pharmacokinetics of 1, 25 (OH) (2) D (3) and 1alpha (OH) D (3) in normal and uraemic men. Nephrol Dial Transplant 2002; 17: 829-842
120. Nielsen PK. A direct inhibitory effect of 1a-hydroxyvitamin D3 on PTH secretion from bovine parathyroid glands. J Am Soc Nephrol 1997; 8: 578A
121. Brown AJ, Ritter CS, Knutson JC, Strugnell SA. The vitamin D prodrugs 1alpha (OH) D2, 1alpha (OH) D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrol Dial Transplant 2006; 21: 644-650.
122. Brandi L, Egfjord M, Olgaard K. Comparison between 1alpha (OH) D3 and 1, 25 (OH) 2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays. Nephron Clin Pract 2005; 99: c128-c137.
123. Brandi L, Egfjord M, Olgaard K. Comparison between 1alpha (OH) D3 and 1, 25 (OH) 2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays. Nephron Clin Pract 2005; 99: c128-c137
124. Koike N, Ichikawa F, Nishii Y, Stumpf WE. Sustained osteoblast nuclear receptor binding of converted 1alpha, 25-dihydroxyvitamin D3 after administration of 3H-1alphahydroxyvitamin D3: a combined receptor autoradiography and radioassay time course study with comparison to 3H-1alpha, 25-dihydroxyvitamin D3. Calcif Tissue Int 1998; 63: 391-395
125. el-Reshaid K, el-Reshaid W, Sugathan T, al-Mohannadi S, Sivanandan R. Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. Am J Nephrol 1997; 17: 505-510
126. Kimura Y, Nakayama M, Kuriyama S, Watanabe S, Kawaguchi Y, Sakai O. Pharmacokinetics of active vitamins D3, 1 alphahydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis. Clin Nephrol 1991; 35: 72-77
127. Moe S, Wazny LD, Martin JE. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. Can J Clin Pharmacol 2008; 15: e36-e43
128. Arenas MD, Muray S, Egea JJ, Millan I, Amoedo L, Gil MT. Comparative study of the efficacy of calcitriol vis-a-vis alfacalcidol in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD). EDTA congres Istanbul June 2005. 2005.
129. Arenas MD, Muray S, Amoedo ML, Egea JJ, Millan I, Gil MT. [A long-term comparative study of calcitriol versus alphacalcidol in patients with secondary hyperparathyroidism on hemodialysis]. Nefrologia 2006; 26: 226-233
130. Slatopolsky E, Finch J, Ritter C et al. A new analog of calcitriol, 19-nor-1, 25-(OH) 2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26: 852-860
131. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1, 25-(OH) 2D3, 19-NOR-1, 25-(OH) 2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997; 30: 105-112
132. Szabo A, Merke J, Beier E, Mall G, Ritz E. 1, 25 (OH) 2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049-1056
133. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432
134. Martin KJ, Gonzalez EA, Gellens ME, Hamm LL, Abboud H, Lindberg J. Therapy of secondary hyperparathyroidism with 19-nor-1alpha, 25-dihydroxyvitamin D2. Am J Kidney Dis 1998; 32: S61-S66
135. Greenbaum LA, Benador N, Goldstein SL et al. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 2007; 49: 814-823
136. Coyne D, Acharya M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276
137. Ross EA, Tian J, Abboud H et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008; 28: 97-106
138. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001; 56: 315-323
139. Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E. Differential effects of acute administration of 19-Nor 1, 25-dihydroxy-vitamin D2 and 1, 25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002; 40: 1283-1288
140. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001; 38: S51-S56
141. Abdul Gafor AH, Saidin R, Loo CY et al. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Nephrology (Carlton) 2009; 14: 488-492
142. Mittman N, Desiraju B, Meyer KB, Chattopadhyay J, Avram MM. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney Int Suppl 2010; S33-S36
143. Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1, 25-dihydroxy-vitamin D3 and 19-nor-1, 25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999; 10: 980-985
144. Nakane M, Fey TA, Dixon DB et al. Differential effects of Vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol 2006; 98: 72-77
145. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1, 25-dihydroxyvitamin D (2) and 1, 25-dihydroxyvitamin D (3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139: 279-284.
146. Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1, 25-(OH) (2) D (2) and 1alphahydroxyvitamin D (2) on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62: 1277-1284
147. Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1, 25-(OH) (2) D (2) and 1alpha-hydroxyvitamin D (2) on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62: 1277-1284
148. Lund RJ, Andress DL, Amdahl M, Williams LA, Heaney RP. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol 2010; 31: 165-170
149. Bailie GR, Johnson CA. Comparative review of the pharmacokinetics of vitamin D analogues. Semin Dial 2002; 15: 352-357
150. Dusso A, Tokumoto A, Brown A, Slatopolsky E. New vitamin D analogs for chronic kidney disease patients. In: Olgaard K, Salusky IB, Silver J, eds. The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Oxford University Press, New York: 2010; 417-441
151. Fernstr MA, Gi VJ, Granroth B et al. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study. Scand J Urol Nephrol 2011;
152. Vervloet MG, Grooteman MP, Wee PMT. Improvde parathyroid hormone levels after conversion from intravenous alfacalcidol to intravenous paricalcitol. ASN Renal Week Meeting. 2006.
153. Frandsen NE, Hansen D, Ostergaard OV. Effect of Paricalcitol on moderate-severe Hyperparathyroidism in chronic hemodialysis patients. ASN Renal Week Meeting. 2008.
154. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490
155. Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K. Long-term effects of intravenous 1 alpha (OH) D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. Nephron 1996; 74: 89-103
156. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38: S45-S50
157. Abboud H, Coyne D, Smolenski O et al. A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. Am J Nephrol 2006; 26: 105-114
158. Llach F, Keshav G, Goldblat MV et al. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1, 25-dihydroxyvitamin D2. Am J Kidney Dis 1998; 32: S48-S54
159. Barreto FC, Barreto DV, Moyses RM et al. K/DOQIrecommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777
160. D'Amour P, Brossard JH. Carboxyl-terminal parathyroid hormone fragments: role in parathyroid hormone physiopathology. Curr Opin Nephrol Hypertens 2005; 14: 330-336
161. Gao P, D'Amour P. Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab 2005; 51: 21-29
162. D'Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH (1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003; 49: 2037-2044
163. Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006; 70: 345-350
164. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2010; 77: 93-100
165. D'Amour P, Brossard JH, Rakel A, Rousseau L, Albert C, Cantor T. Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem 2005; 51: 169-176
166. Joly D, Drueke TB, Alberti C et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008; 51: 987-995
167. Schmitt CP, Homme M, Schaefer F. Structural organization and biological relevance of oscillatory parathyroid hormone secretion. Pediatr Nephrol 2005; 20: 346-351
168. Lips P, Chapuy MC, Dawson-Hughes B, Pols HA, Holick MF. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999; 9: 394-397
169. Wallace AM, Gibson S, de la Hunty A, Lamberg-Allardt C, Ashwell M. Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids 2010; 75: 477-488
170. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348: 1656-1663
171. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95: 578-585
172. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21: 1187-1196.
173. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
174. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
175. Wesseling-Perry K, Pereira RC, Sahney S et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011; 79: 112-119
176. Weber T, Ammer M, Rammer M et al. Noninvasive determination of carotid-femoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J Hypertens 2009; 27: 1624-1630
177. SphygmoCor Concise Software Guide. (2008). 2011. www.atcormedical.com
178. Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S. Pulse-wave morphology and pulse-wave velocity in healthy human volunteers: examination conditions. Scand J Clin Lab Invest 2006; 66: 385-394
179. Laurent S, Cockcroft J, Van BL et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605
180. Hommel K, Rasmussen S, Kamper AL, Madsen M. Regional and social inequalities in chronic renal replacement therapy in Denmark. Nephrol Dial Transplant 2010; 25: 2624-2632
181. Brown AJ, Zhong M, Finch J, Ritter C, Slatopolsky E. The roles of calcium and 1, 25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands. Endocrinology 1995; 136: 1419-1425
182. Wiese RJ, Uhland-Smith A, Ross TK, Prahl JM, DeLuca HF. Upregulation of the vitamin D receptor in response to 1, 25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992; 267: 20082-20086
183. Brown AJ, Zhong M, Finch J et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996; 270: F454-F460
184. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
185. Fishbane S, Shapiro WB, Corry DB et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3: 1718-1725
186. Vulpio C, Maresca G, Distasio E et al. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size. Hemodial Int 2011; 10.1111/j.1542-4758.2010.00514. x [doi].
187. Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996; 11: 2430-2438
188. Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996; 11: 2430-2438
189. Bergwitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010; 61: 91-104
190. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16: 200-257
191. Panda DK, Miao D, Bolivar I et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279: 16754-16766
192. Issa LL, Leong GM, Sutherland RL, Eisman JA. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res 2002; 17: 879-890
193. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
194. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000; 11: 1141-1152
195. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443
196. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994; 68: 221-228
197. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942
198. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38: 434-438
199. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
200. Covic A, Haydar AA, Bhamra-Ariza P, Gusbeth-Tatomir P, Goldsmith DJ. Aortic pulse wave velocity and arterial wave reflections predict the extent and severity of coronary artery disease in chronic kidney disease patients. J Nephrol 2005; 18: 388-396.
201. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620.
202. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620
203. Shiota J, Watanabe M. [Association of mineral and bone disorder with increasing PWV in CKD 1-5 patients]. Nippon Jinzo Gakkai Shi 2007; 49: 121-124
204. Andrade J, Er L, Ignaszewski A, Levin A. Exploration of association of 1, 25-OH2D3 with augmentation index, a composite measure of arterial stiffness. Clin J Am Soc Nephrol 2008; 3: 1800-1806
205. Shroff R, Egerton M, Bridel M et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008; 19: 1239-1246
206. Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S. Reproducibility of pulse-wave analysis and pulse-wave velocity determination in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 594-600
207. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
208. Dong Y, Stallmann-Jorgensen IS, Pollock NK et al. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab 2010; 95: 4584-4591
209. Noonan W, Koch K, Nakane M et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant 2008; 23: 3824-3830
210. Hansen D, Brandi L, Rasmussen K. [Vitamin D, cardiovascular disease and mortality in patients with kidney disease]. Ugeskr Laeger 2009; 171: 3684-3689
211. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003; 88: 327-331
212. Yuan W, Pan W, Kong J et al. 1, 25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-29830
213. Mizobuchi M, Morrissey J, Finch JL et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806
214. Deb DK, Sun T, Wong KE et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 2010; 77: 1000-1009.
215. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008; 105: 15896-15901
216. de ZD, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551
217. Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81
218. Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 2007; 104: 16810-16815
219. Kong J, Kim GH, Wei M et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 2010; 177: 622-631
220. Mahmud A, Feely J. Arterial stiffness and the reninangiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2004; 5: 102-108
221. Reynolds JL, Skepper JN, McNair R et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005; 16: 2920-2930
222. Briese S, Wiesner S, Will JC et al. Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. Nephrol Dial Transplant 2006; 21: 1906-1914
223. Shroff RC, Donald AE, Hiorns MP et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18: 2996-3003
224. Ogawa T, Ishida H, Akamatsu M et al. Relation of oral 1alphahydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients. Heart Vessels 2010; 25: 1-6
225. Jono S, Nishizawa Y, Shioi A, Morii H. 1, 25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998; 98: 1302-1306
226. Krog M, Ejerblad S, Eriksson I, Johansson H. Arterial calcifications in uraemic rats treated with 1-alphahydroxycholecalciferol and parathyroidectomy. Scand J Urol Nephrol 1984; 18: 227-239
227. Krog M, Ejerblad S, Ericsson JL. Uraemic and 1-alphahydroxycholecalciferol induced aortic lesions. Exp Pathol 1988; 35: 101-114
228. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307
229. Shalhoub V, Shatzen E, Henley C et al. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int 2006; 79: 431-442
230. Cardus A, Panizo S, Parisi E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-866
231. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715
232. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509-1519
233. Baker LR, Muir JW, Sharman VL et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 1986; 26: 185-191
234. Alborzi P, Patel NA, Peterson C et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255
235. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808
236. Porazko T, Kuzniar J, Kusztal M et al. Increased aortic wall stiffness associated with low circulating fetuin A and high Creactive protein in predialysis patients. Nephron Clin Pract 2009; 113: c81-c87
237. Provan SA, Angel K, Semb AG et al. Early Prediction of Increased Arterial Stiffness in Patients with Chronic Inflammation: A 15-year Followup Study of 108 Patients with Rheumatoid Arthritis. J Rheumatol 2011; 38: 606-12
238. Stompor T, Rajzer M, Sulowicz W et al. An association between aortic pulse wave velocity, blood pressure and chronic inflammation in ESRD patients on peritoneal dialysis. Int J Artif Organs 2003; 26: 188-195
239. Maki-Petaja KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des 2009; 15: 290-303
240. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-390
241. Larsson TE. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant 2010; 25: 1376-1381.
242. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116
243. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116
244. Nishi H, Nii-Kono T, Nakanishi S et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005; 101: c94-c99
245. Saji F, Shigematsu T, Sakaguchi T et al. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha}, 25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 2010; 299: F1212-F1217
246. Wesseling-Perry K, Pereira RC, Wang H et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94: 511-517
247. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 4957-4960
248. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21: 1427-1435
249. Cancela AL, Oliveira RB, Graciolli FG et al. Fibroblast Growth Factor 23 in Hemodialysis Patients: Effects of Phosphate Binder, Calcitriol and Calcium Concentration in the Dialysate. Nephron Clin Pract 2010; 117: c74-c82
250. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005; 67: 1120-1125
251. Weiss MJ, Ray K, Henthorn PS, Lamb B, Kadesch T, Harris H. Structure of the human liver/bone/kidney alkaline phosphatase gene. J Biol Chem 1988; 263: 12002-12010
252. Jorna FH, Tobe TJ, Huisman RM, de Jong PE, Plukker JT, Stegeman CA. Early identification of risk factors for refractory secondary hyperparathyroidism in patients with longterm renal replacement therapy. Nephrol Dial Transplant 2004; 19: 1168-1173
253. Fletcher S, Jones RG, Rayner HC et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997; 75: 412-419
254. Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358-363
255. Pierides AM, Skillen AW, Ellis HA. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1 alpha OHD3 and 1, 25 (OH) 2D3. J Lab Clin Med 1979; 93: 899-909
256. Shimamatsu K, Maeda T, Harada A et al. 1-year controlled trial of 1 alpha-hydroxycholecalciferol in patients on maintenance hemodialysis. Nephron 1981; 28: 70-75
257. Shimamatsu K, Maeda T, Harada A et al. 1-year controlled trial of 1 alpha-hydroxycholecalciferol in patients on maintenance hemodialysis. Nephron 1981; 28: 70-75
258. Urena P, de Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156
259. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008; 74: 655-663
260. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203
261. Mosekilde L, Brot C, Hyldstrup L et al. [The vitamin D status of the Danish population needs to be improved]. Ugeskr Laeger 2005; 167: 895-897
262. Del VE, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25 (OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007; 11: 315-321
263. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503-510
264. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: c132-c138
265. Cuppari L, Garcia Lopes MG, Kamimura MA. Vitamin D biology: from the discovery to its significance in chronic kidney disease. J Ren Nutr 2011; 21: 113-116
266. Jacob AI, Sallman A, Santiz Z, Hollis BW. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr 1984; 114: 1313-1319
267. Michaud J, Naud J, Ouimet D et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 2010; 21: 1488-1497
268. Bell NH, Shaw S, Turner RT. Evidence that 1, 25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitamin D in man. J Clin Invest 1984; 74: 1540-1544
269. Haddad JG, Stamp TC. Circulating 25-hydroxyvitamin D in man. Am J Med 1974; 57: 57-62
270. Smith JE, Goodman DS. The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J Clin Invest 1971; 50: 2159-2167
271. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
272. Holick MF. Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am 2010; 39: 381-400
273. Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1, 25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206: 1188-1190
274. Gallieni M, Kamimura S, Ahmed A et al. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 1995; 268: F746-F753
275. Repo JM, Rantala IS, Honkanen TT et al. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 2007; 72: 977-984